Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAPA-DEINE #3 vs ANEXSIA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen produces analgesia and antipyresis via central COX-2 inhibition and activation of descending serotonergic pathways. Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits ascending pain pathways and alters pain perception.
ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.
Relief of mild to moderately severe pain,Cough suppression (off-label)
Relief of moderate to moderately severe pain
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 12 tablets in 24 hours. Each tablet contains acetaminophen 300 mg, codeine phosphate 30 mg.
50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.
Codeine: 2.5-3 hours; Acetaminophen: 2-3 hours; Morphine (active metabolite): 2-3 hours. In hepatic impairment, codeine half-life may extend to 4-6 hours.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (Cr Cl <30 m L/min).
Acetaminophen is primarily metabolized via glucuronidation and sulfation, with a minor pathway via CYP2E1 to NAPQI (toxic metabolite). Codeine is metabolized by CYP2D6 to morphine (active), by CYP3A4 to norcodeine, and by glucuronidation.
Hydrocodone is metabolized via CYP2D6 and CYP3A4 to hydromorphone and norhydrocodone. Acetaminophen is primarily metabolized via hepatic glucuronidation and sulfation; a minor pathway via CYP2E1 produces NAPQI, which is detoxified by glutathione.
Primarily renal (90% as glucuronide conjugates, 10% as morphine, codeine, and norcodeine). Biliary/fecal elimination accounts for <5%.
Approximately 70% renal (unchanged drug and metabolites), 20% biliary/fecal, 10% other.
Codeine: ~25% bound to albumin; Acetaminophen: 10-25% bound; Morphine: 30-35% bound to albumin.
Approximately 95% bound to plasma albumin and alpha-1-acid glycoprotein.
Codeine: 3-6 L/kg; Acetaminophen: 0.9-1.0 L/kg; Morphine: 3-4 L/kg. Codeine's high Vd indicates extensive tissue distribution.
0.2-0.4 L/kg, indicating limited extravascular distribution primarily confined to plasma and interstitial fluid.
Codeine: 53% (oral) due to first-pass metabolism; Acetaminophen: 85-90% (oral); Morphine (from codeine): 0.05-10% depending on CYP2D6 phenotype.
Oral: 80-90%; Intramuscular: 90-100%; Rectal: 70-80%.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours. Avoid in severe renal impairment due to acetaminophen accumulation.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: 50% dose reduction; GFR <15 m L/min: avoid use.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50% or extend interval to every 8 hours; Child-Pugh class C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: 50% dose reduction; Child-Pugh C: avoid use.
Not recommended for children under 12 years. For adolescents 12-18 years: 1 tablet orally every 4-6 hours as needed, max 6 tablets/day. Weight-based dosing not established.
1-2 mg/kg/dose orally every 6 hours; maximum 6 mg/kg/day.
Initiate at lowest dose, 1 tablet every 6 hours, and titrate cautiously due to increased sensitivity and risk of acetaminophen hepatotoxicity. Monitor renal and hepatic function.
Initiate at 25 mg every 6 hours; increase cautiously; monitor renal function.
Risk of medication errors: Confusion between different concentrations and dosage forms can lead to accidental overdose and death. Respiratory depression: Life-threatening respiratory depression may occur, especially in elderly, cachectic, or debilitated patients. Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy can result in neonatal withdrawal. CYP2D6 metabolism: Ultra-rapid metabolizers of codeine convert codeine to morphine faster, leading to higher morphine levels and risk of fatal respiratory depression. Accidental exposure: Ingesting even one dose by a child can be fatal.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity from acetaminophen.
Acetaminophen hepatotoxicity: Severe liver injury, including acute liver failure, may occur with doses exceeding 4 g/day or with pre-existing liver disease. Respiratory depression: Use with caution in patients with respiratory compromise. Drug dependence and abuse: Codeine has addiction potential and may cause physical and psychological dependence. Serotonin syndrome: Concomitant use with serotonergic drugs may cause serotonin syndrome. CYP2D6 ultra-rapid metabolizers: Increased risk of morphine toxicity. Use in children: Not recommended for children under 12 years; for those 12-18 years, avoid if at risk of respiratory depression. Avoid alcohol and other CNS depressants.
Risk of respiratory depression, especially in elderly or debilitated patients; adrenal insufficiency; severe hypotension; seizures; opioid-induced hyperalgesia; acetaminophen hepatotoxicity (avoid exceeding 4 g/day); serotonin syndrome if used with serotonergic agents.
Hypersensitivity to acetaminophen, codeine, or any component. Significant respiratory depression. Acute or severe bronchial asthma. Hypercapnia. Paralytic ileus. Use in children under 12 years of age. Use in children 12-18 years with compromised respiratory function. Use in children 12-18 years after tonsillectomy or adenoidectomy. Use in patients of any age with known CYP2D6 ultra-rapid metabolizer status.
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting; known or suspected GI obstruction; severe hepatic impairment; concomitant use of MAOIs or within 14 days.
Grapefruit and grapefruit juice may inhibit CYP2D6, reducing codeine efficacy. Avoid excessive alcohol; increases acetaminophen hepatotoxicity.
Avoid alcohol; may increase risk of hepatotoxicity and GI bleeding. Limit caffeine intake from coffee, tea, cola, or energy drinks due to added caffeine content. High-fat meals may delay absorption; take on empty stomach for faster onset if tolerated.
Pregnancy Category C prior to FDA pregnancy labeling rule. First trimester: Risk of neural tube defects and oral clefts with codeine component; limited data on papaverine. Second trimester: Potential for fetal growth restriction with chronic use; codeine associated with respiratory depression. Third trimester: Risk of neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery; papaverine may cause fetal bradycardia.
First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus arteriosus and oligohydramnios due to fetal renal effects; avoid use after 30 weeks gestation.
Codeine is excreted into breast milk with M/P ratio approximately 2.5; risk of CNS depression in breastfed infants, especially in CYP2D6 ultra-rapid metabolizers. Papaverine excretion unknown but considered low. High dose or prolonged use not recommended; monitor infant for sedation and respiratory depression.
Excreted into breast milk in low concentrations (M/P ratio not established). Not recommended during breastfeeding due to potential for adverse effects in the infant, including renal impairment and gastrointestinal bleeding.
Codeine undergoes increased clearance in pregnancy due to enhanced hepatic metabolism and renal perfusion; half-life reduced. Consider dose adjustment upward if pain poorly controlled, but avoid high doses. Papaverine metabolism may be induced but clinical relevance unknown. Use lowest effective dose for shortest duration.
Dose adjustment not generally required; however, due to increased renal clearance in pregnancy, shortened dosing intervals may be necessary for sustained efficacy. Use lowest effective dose for shortest duration.
Contains codeine (prodrug converted to morphine via CYP2D6) and acetaminophen. Avoid in children <12 years due to risk of respiratory depression. Check CYP2D6 status if ultra-rapid metabolizer. Never exceed 4g/day acetaminophen. Monitor for constipation, abuse potential.
ANEXSIA is a combination analgesic containing paracetamol, ibuprofen, and caffeine. It is contraindicated in patients with active peptic ulcer disease, severe hepatic impairment, or hypersensitivity to NSAIDs. Avoid concurrent use with other NSAIDs or paracetamol-containing products. Monitor renal function in elderly or dehydrated patients. Caffeine may exacerbate anxiety or insomnia.
Take only as prescribed; do not exceed 4 grams of acetaminophen per day.,Avoid alcohol; risk of liver damage.,May cause drowsiness; avoid driving or operating machinery.,Do not use with other acetaminophen-containing products.,Report signs of liver injury: yellow skin/eyes, dark urine, abdominal pain.
Do not exceed recommended dose; overdosage of paracetamol can cause liver damage.,Take with food or milk to reduce gastrointestinal upset.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,Discontinue use and consult if signs of allergic reaction, GI bleeding, or liver problems occur.,Caffeine may cause nervousness, insomnia, or increased heart rate; limit caffeine-containing foods and beverages.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAPA-DEINE #3 vs ANEXSIA, answered by our medical review team.
PAPA-DEINE #3 is a Opioid Analgesic Combination that works by Acetaminophen produces analgesia and antipyresis via central COX-2 inhibition and activation of descending serotonergic pathways. Codeine is a prodrug converted to morphine, a mu-opioid receptor agonist, which inhibits ascending pain pathways and alters pain perception.. ANEXSIA is a Opioid Analgesic Combination that works by ANEXSIA is a combination of hydrocodone and acetaminophen. Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, altering pain perception and emotional response to pain. Acetaminophen's analgesic mechanism is not fully understood but involves inhibition of COX enzymes in the CNS and modulation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAPA-DEINE #3 and ANEXSIA depend on the specific clinical indication. These are both Opioid Analgesic Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAPA-DEINE #3 is: 1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 12 tablets in 24 hours. Each tablet contains acetaminophen 300 mg, codeine phosphate 30 mg.. The standard adult dose of ANEXSIA is: 50-100 mg orally every 4-6 hours as needed; maximum 400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAPA-DEINE #3 and ANEXSIA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAPA-DEINE #3 is classified as Category C. Pregnancy Category C prior to FDA pregnancy labeling rule. First trimester: Risk of neural tube defects and oral clefts with codeine component; limited data on papaverine. Second t. ANEXSIA is classified as Category C. First trimester: Data are limited; no increased risk of major malformations reported in small studies. Second and third trimesters: Associated with premature closure of the ductus . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.